Bicontinuous cyclosporin a loaded water-AOT/Tween 85-isopropylmyristate microemulsion: structural characterization and dermal pharmacokinetics in vivo.
Topical delivery of Cyclosporin A (CysA) is of great interest for the treatment of autoimmune skin disorders. Microemulsion systems prepared by AOT/Tween85/isopropyl myristate (IPM)/water possessing a potentially improved skin bioavailability of CysA were designed. The structure of microemulsions was investigated by diffusion-ordered NMR spectroscopy (DOSY) and differential scanning calorimetry (DSC) measurements. The DOSY measurements indicated the presence of bicontinuous and water-in-oil microemulsions depending on microemulsion composition. The DSC measurement confirmed that the microemulsion containing 30.0 wt% water was bicontinuous type, in agreement with the DOSY findings. We also evaluated the therapeutic advantage of dermal administration of CysA in rat model. Local (subcutaneous and skin), systemic concentrations and organ distribution (liver and kidney) were evaluated serially following topical and oral application of the drug. In rat dermal applied with the bicontinuous microemulsion containing CysA, the deposition of the drug into skin and subcutaneous fat was respectively almost 30 and 15-fold higher than the concentrations compared with oral administration. Systemic distribution in blood, liver and kidney was much lower following topical administration than that of following oral administration. With high local concentrations and minimal distribution to other organs via the circulation, topical microemulsion vehicle loaded with CysA might deliver maximal therapeutic effect to local tissue while avoiding side effects seen with systemic therapy. The histopathological findings revealed that the new bicontinuous microemulsion was a safe vehicle for topical drug delivery of CysA.
Liu
Hongzhuo
H
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Wang
Yongjun
Y
Lang
Yiyong
Y
Yao
Huimin
H
Dong
Yang
Y
Li
Sanming
S
D000284:Administration, Oral; D000287:Administration, Topical; D000336:Aerosols / Q000737:chemistry; D000818:Animals; D002152:Calorimetry, Differential Scanning; D016572:Cyclosporine / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000633:toxicity; D016503:Drug Delivery Systems; D004655:Emulsions / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics* / Q000633:toxicity; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009226:Myristates / Q000737:chemistry; D011136:Polysorbates / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000378:metabolism* / Q000473:pathology
D000336:Aerosols; D004655:Emulsions; D009226:Myristates; D011136:Polysorbates; C008205:isopropyl myristate; D016572:Cyclosporine